blood-cancer
Study of 407 lymphoma cases from Guatemala found SSTR2 expression in 43% of EBV-positive classical Hodgkin lymphoma vs. 0% of EBV-negative cHL. Other EBV-associated lymphomas were largely SSTR2-negative. In EBV-negative NHL, SSTR2 associated with higher-grade B-cell lymphomas (17% of DLBCL, 17%…
breast-cancer
Retrospective study of 44 HER2-positive breast cancer patients treated with 12-week neoadjuvant weekly paclitaxel + carboplatin + trastuzumab + pertuzumab (12wTCHP): 61% pCR rate (75% ER-negative, 54% ER-positive), only 2 recurrences (5%) at 30-month median follow-up, no treatment deaths.…
breast-cancer
This review focuses on surface-functionalized polymeric nanoparticles for active targeting of breast cancer cells. Ligands like folic acid (folate receptor), hyaluronic acid (CD44), aptamers, and peptides (HER2) enable receptor-mediated endocytosis, improving drug delivery to cancer cells while…
colorectal-cancer
Full-length 16S rRNA sequencing using Oxford Nanopore Technology with custom demultiplexing software provides robust species-level discrimination within Fusobacterium, enabling accurate identification of F. animalis (the key CRC driver) vs. F. nucleatum sensu stricto. Validated in whole cells, DNA…
bladder-cancer
In 59 mUC patients on maintenance avelumab, hypoalbuminemia was the only independent predictor of poor PFS (HR 2.70, p=0.013). Hypoalbuminemia patients had median PFS of 3.3 vs. 12.0 months and OS of 9.3 months vs. not reached compared to normal albumin patients.
lung-cancer
17 metastatic lung cancer and melanoma treatment responders who received CALM therapy described their experience. Four themes emerged: twilight zone between illness/health, ongoing uncertainty, struggling to adapt, and shift over time. CALM was valued for safe processing space, addressing…
cervical-cancer
HPV genotyping of 429 cervical swabs from Northeast India found 17.25% positivity. Among positives, HPV-16 was 52.70%, HPV-59 was 13.51%, HPV-18 was 8.10%, and HPV-58 was 5.4%. HPV-58 positive women showed cytological abnormalities; one HPV-59 case had poorly differentiated malignancy. Standard…
cervical-cancer
Single-cell RNA and TCR sequencing on paired tumor core and edge samples from 13 cervical squamous cell carcinoma patients found tumor cores had higher T cell exhaustion. Four exhausted CD8+ T cell subsets were identified; a stress-associated HSP-expressing subset inversely correlated with survival…
blood-cancer
CCDC137 is overexpressed in AML and correlates with poor prognosis. CCDC137 stabilizes S100A6 protein, which then activates the PI3K/AKT signaling pathway driving AML cell proliferation and cell cycle progression. This CCDC137→S100A6→PI3K/AKT axis is a novel AML therapeutic target.
breast-cancer
Systematic comparison of four breast cancer chemotherapy regimens in female mice found paclitaxel caused the most prolonged central pro-inflammatory signaling and cisplatin caused the most sustained gut microbiome disruption. Cyclophosphamide and doxorubicin had more modest effects on the gut-brain…
brain-cancer
This review synthesizes current knowledge on methylation—affecting DNA, histones, and RNA—in pituitary neuroendocrine tumor (PitNET) biology. WHO 2022 classification puts molecular biology at the center of PitNET diagnosis. Methylation drives tumor initiation and progression through mutual…
breast-cancer
Molecular dynamics simulations of HER2 D769H and D769Y mutations showed contrasting effects. D769H destabilized the drug complex (equilibrium at 100 ps vs. 150 ps for wild-type, suggesting reduced drug retention). D769Y enhanced ligand binding beyond wild-type strength. Both mutations increased…
